About ImaginAb
ImaginAb is a Healthcare company based in Los Angeles (United States) founded in 2007. ImaginAb is focused on developing advanced immuno-oncology imaging technologies. It operates on a HealthTech model. ImaginAb has raised $59.64 million across 6 funding rounds from investors including Novartis, Theravance Biopharma and HHS. ImaginAb offers products and services including CD8 ImmunoPET and PSMA Optical Imaging. Its focus areas include Biotechnology and Immuno-Oncology. Its legal entity is ImaginAb, Inc. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.
Company details
ImaginAb is engaged in the development of cutting-edge radiopharmaceutical imaging technologies, primarily through its CD8 ImmunoPET agent, which is designed to provide detailed visual profiles of immunity status in patients. The company operates in the healthcare and biotechnology sectors, targeting immuno-oncology and autoimmune diseases. Solutions are offered to enhance patient care paths by enabling physicians to visualize treatment impacts before, during, and after therapy. Additionally, pipeline innovations include optical imaging for prostate and renal cancer, aiming to transform diagnostic and therapeutic approaches in oncology.
- Headquarters Los Angeles, United States
- SectorsHealthcare
- Phone•••• ••••
- Website imaginab.com
- Social LinkedIn X YouTube
- Legal Name Imaginab, Inc.
- Total Equity Funding$59.64M (USD)
in 6 rounds
- Latest Funding Round$12.8M (USD), Series C
Jun 2021
- InvestorsNovartis
& 12 more
Products & Services of ImaginAb
ImaginAb offers a comprehensive portfolio of products and services, including CD8 ImmunoPET and PSMA Optical Imaging.
Advanced imaging agent for visualizing CD8 cell activity.
Optical imaging solution for prostate and renal cancer.
Apps and channels of ImaginAb
its YouTube channel ImaginAb Inc has 9 subscribers and 3 videos.
Videos from ImaginAb
The most watched videos on ImaginAb's YouTube channel, ImaginAb Inc (9 subscribers). Click a video to play it here.
More on ImaginAb Inc.
Funding Insights of ImaginAb
ImaginAb has successfully raised a total of $59.64M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $12.8 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $59.64M
- Total Rounds 6
- Last Round Series C — $12.8M
- First Round $995,229
(Sep 2011)
- Investors Count 13
All 6 funding rounds of ImaginAb with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $12.8M | Series C | – | Norgine Ventures, Theravance Biopharma | |
| Sep 2017 | $8M | Series B | – | Adage Capital Management | |
| Apr 2016 | $5.34M | Series B | – | – | – |
| May 2014 | $21M | Series B | – | Merieux Equity Partners | |
| Apr 2012 | $12.5M | Series A | – | Novartis | |
| Sep 2011 | $995,229 | Grant | – | – |
13 investors in total: 12 institutional and 1 angel.
Investors in ImaginAb
ImaginAb has secured backing from 13 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Novartis, Theravance Biopharma and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and strategic support are provided by Raptor Group. | raptorgroup.com | Boston, United States | ||
| norgineventures.com | ||||
Stage agnostic VC firm investing primarily in the US | cycadvc.com | Santa Barbara, United States | ||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Pivate equity firm that focuses on investing in healthcare and nutrition companies | merieux-partners.com | Lyon, France | ||
Therapeutics for inflammatory and immunological diseases are developed. | 2001 | theravance.com | Francisco, United States | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Research on cancer immunotherapy is conducted to develop treatments. | parkerici.org | San Francisco, United States | ||
Provides vet-to-vet assistance, resources, and outreach for veterans in need. | 1985 | nvf.org | Los Angeles, United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for ImaginAb
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ImaginAb
18 people are tracked at ImaginAb (5 in leadership, 11 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
William Le | VP, Global Operations | Leadership |
Ian Wilson | Chief Executive Officer | Leadership |
Jill Durkin | Vp, Financial Planning And Strategy | Leadership |
David Fractor | CFO | Leadership |
Kristin Schmiedehausen | VP, Medical Affairs | Leadership |
Jeffrey L. Evelhoch | Scientific Advisor | Board & advisors |
K. Leonard Judson | Director | Board & advisors |
Anna M. Wu | Founder & Chief Scientific Advisor | Board & advisors |
Jules Haimovitz | Director | Board & advisors |
Padmanee Sharma | Scientific Advisor | Board & advisors |
Tim Irish | Director | Board & advisors |
Friedhelm Blobel | Director | Board & advisors |
Antoni Ribas | Scientific Advisor | Board & advisors |
David Mankoff | Scientific Advisor | Board & advisors |
Daniel D. Von Hoff | Scientific Advisor | Board & advisors |
James P. Allison | Scientific Advisor | Board & advisors |
Kathleen Brady | Quality Assurance Manager | Team |
Tiffany Kersting | Clinical Trial Manager | Team |
Complete people profiles for ImaginAb
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ImaginAb
3 dated milestones of ImaginAb across 14 years, from founding to its latest funding, stage changes and deals.
- Founded ImaginAb is founded.
- Funding First funding round of $995K.
- Funding Latest funding round, Series C, of $12.8M.
Competitors of ImaginAb
ImaginAb has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. |
Detailed competitors of ImaginAb
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ImaginAb
The website of ImaginAb (imaginab.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▲ 95% vs previous month
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as ImaginAb (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Imaginab
Complete news archive for ImaginAb
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImaginAb
ImaginAb was founded in 2007 and raised its 1st funding round 4 years after it was founded.
ImaginAb is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
ImaginAb is a funded company, having raised a total of $59.64M across 6 funding rounds to date. The company's 1st funding round was a Grant of $995.23K, raised on Sep 2011.
ImaginAb is engaged in the development of cutting-edge radiopharmaceutical imaging technologies, primarily through its CD8 ImmunoPET agent, which is designed to provide detailed visual profiles of immunity status in patients. The company operates in the healthcare and biotechnology sectors, targeting immuno-oncology and autoimmune diseases. Solutions are offered to enhance patient care paths by enabling physicians to visualize treatment impacts before, during, and after therapy. Additionally, pipeline innovations include optical imaging for prostate and renal cancer, aiming to transform diagnostic and therapeutic approaches in oncology.
ImaginAb's top competitors include Guardant Health, Foundation Medicine and ArcherDX.
ImaginAb offers CD8 ImmunoPET and PSMA Optical Imaging.
ImaginAb has 13 investors. Key investors include Novartis, Theravance Biopharma, HHS, Momentum Bioscience, and Raptor Group.
ImaginAb operates through Imaginab, Inc..